Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2012
08/14/2012US8242115 Materials and methods to potentiate cancer treatment
08/14/2012US8242109 Compositions and methods relating to novel compounds and targets thereof
08/14/2012US8242098 Methods of treating hormone-related conditions using thio-oxindole derivatives
08/14/2012US8242090 Vascular therapeutics
08/14/2012US8242088 Carrier vectors through an epithelium with tight junctions
08/14/2012US8242084 Dimerized peptide
08/14/2012US8242079 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
08/14/2012US8241899 Anti-TNF antibodies, compositions, methods and uses
08/14/2012US8241848 Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
08/14/2012US8241668 Polymers contqining ester, thioester or amide groups in backbone which degrade into bioactive material upon hydrolysis
08/14/2012US8241663 Liposome preparation
08/14/2012US8241637 DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof
08/14/2012CA2632078C Methods of inducing terminal differentiation
08/14/2012CA2628193C Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
08/14/2012CA2574829C Bicyclic amides as kinase inhibitors
08/14/2012CA2552855C Azabicyclooctan-3-one derivatives and use thereof
08/14/2012CA2501821C Bispecific anti-erb-b antibodies and their use in tumor therapy
08/14/2012CA2457485C Combination motif immune stimulatory oligonucleotides with improved activity
08/14/2012CA2452075C Sustained release delivery system
08/14/2012CA2442300C Cd8.alpha. + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
08/14/2012CA2436326C Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
08/14/2012CA2386069C Indolyl-3-glyoxylic acid derivatives as antitumor agents
08/14/2012CA2373274C Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
08/09/2012WO2012106713A2 Targeted nanoparticle conjugates
08/09/2012WO2012106702A2 Treatment of leukemia
08/09/2012WO2012106671A1 Psa capture agents, compositions, methods and preparation thereof
08/09/2012WO2012106669A2 Foxc1 antibodies and methods of their use
08/09/2012WO2012106540A1 Methods of using alk inhibitors
08/09/2012WO2012106461A2 Combination therapy for treatment of cancer
08/09/2012WO2012106393A2 Withanolide isolated from physalis longifolia and analogs and methods of use thereof
08/09/2012WO2012106368A2 Methods for inhibiting prostate cancer
08/09/2012WO2012106343A2 Hdac inhibitors and therapeutic methods using the same
08/09/2012WO2012106313A2 Ubiquitin interacting motif peptides as cancer therapeutics
08/09/2012WO2012105873A1 Hydrated n-fullerene amino acids, method for producing the latter, and pharmaceutical compositions on the basis thereof
08/09/2012WO2012105872A1 Homo- and hetero-polyamino-acid derivatives of fullerene с60, method for producing same, and pharmaceutical compositions based on said derivatives
08/09/2012WO2012105797A2 Structure having nanoantenna and method for manufacturing same
08/09/2012WO2012105532A1 Novel use of maltotriosyl transferase
08/09/2012WO2012105521A1 Externally-used drug for treating skin disorder and method for producing same
08/09/2012WO2012105486A1 Tegafur-containing composition for single daily and alternate-day dosing
08/09/2012WO2012105475A1 Therapeutic or prophylactic agent for cachexia
08/09/2012WO2012105224A1 Vaccine adjuvant
08/09/2012WO2012105219A1 Antibody therapy effect-enhancing drug
08/09/2012WO2012104875A1 Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof
08/09/2012WO2012104857A1 Amidobenzothiazoles and process for the preparation thereof
08/09/2012WO2012104822A1 Combinations comprising macitentan for the treatment of glioblastoma multiforme
08/09/2012WO2012104788A2 Anti-angiogenic compounds, pharmaceutical compositions containing same, and use thereof
08/09/2012WO2012104776A1 Novel heterocyclic derivatives
08/09/2012WO2012104581A1 Anti-tace antibody molecules and their uses
08/09/2012WO2012104569A1 Composition of monoterpenoids for the treatment of cancer
08/09/2012WO2012104568A1 Compositions of monoterpenoids for stimulating the immune system
08/09/2012WO2012104461A1 Development and use of polymer nanoparticles comprising poly(epsilon-caprolactone) and doxorubicin
08/09/2012WO2012104388A1 New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
08/09/2012WO2012104344A1 Human antibodies and antibody-drug conjugates against cd74
08/09/2012WO2012104241A1 Combinations of aromatase inhibitors and antioxidants
08/09/2012WO2012103813A1 Danshensu and chuanxiongqin derivatives, process for preparation, and use thereof
08/09/2012WO2012103810A1 Certain chemical entities, compositions, and methods
08/09/2012WO2012103787A1 Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
08/09/2012WO2012103785A1 Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition
08/09/2012WO2012103784A1 Nitrogen-containing artemisinin dimers, preparation methods and uses thereof
08/09/2012WO2012103783A1 Use of artemisine derivatives and pharmaceutical salts thereof
08/09/2012WO2012103634A1 Cellulose-based nanoparticles for drug delivery
08/09/2012WO2012082841A9 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
08/09/2012WO2012080985A3 Insecticide cry proteins of bacillus thuringiensis with anti-cancer activity
08/09/2012WO2012078695A9 Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
08/09/2012WO2012075484A9 Novel drug targets to overcome de novo drug-resistance in multiple myeloma
08/09/2012WO2012075342A3 Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody
08/09/2012WO2012075253A3 Pharmaceutical compositions
08/09/2012WO2012069836A3 Biologically active complex and its preparation
08/09/2012WO2012068073A3 Therapeutic and diagnostic applications targeting tnk-1
08/09/2012WO2012040323A8 Multimeric il-15 soluble fusion molecules and methods of making and using same
08/09/2012WO2011159769A3 Indane estrogen receptor modulators and uses thereof
08/09/2012WO2011083091A8 Methods for treating pancreatic cancer
08/09/2012US20120204281 Drg11-responsive (dragon) gene family
08/09/2012US20120204280 Drg11-responsive (dragon) gene family
08/09/2012US20120203052 Therapeutic regimen for treating cancer
08/09/2012US20120203051 Treatment of cancer using the sodium salt of a benzoic acid derivative
08/09/2012US20120203050 Metallic nanoparticles, preparation and uses thereof
08/09/2012US20120202981 Novel guanosine-rich modified oligonucleotides and antiproliferative activity thereof
08/09/2012US20120202883 Effects of idh1 and idh2 mutations on the cellular metabolome
08/09/2012US20120202874 Antisense oligonucleotide modulation of stat3 expression
08/09/2012US20120202873 RNAi Probes Targeting Cancer-Related Proteins
08/09/2012US20120202872 Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer
08/09/2012US20120202871 Cationic lipids and methods for the delivery of therapeutic agents
08/09/2012US20120202862 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
08/09/2012US20120202861 Novel estrogen receptor ligands
08/09/2012US20120202857 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
08/09/2012US20120202851 Pim kinase inhibitors and methods of their use
08/09/2012US20120202844 Crystal Forms of Kinase Inhibitors
08/09/2012US20120202843 H3K27me3 and Cancer
08/09/2012US20120202841 Topical Compositions Comprising Ascomycins
08/09/2012US20120202840 Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases
08/09/2012US20120202836 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
08/09/2012US20120202835 Combination
08/09/2012US20120202833 Tricyclic pyrazolopyrimidine derivatives
08/09/2012US20120202832 Kinase inhibitors, prodrug forms thereof and their use in therapy
08/09/2012US20120202831 Pharmaceutical Formulation
08/09/2012US20120202827 Sulfoxide derivatives for the treatment of tumors
08/09/2012US20120202822 Combination
08/09/2012US20120202818 Ureidophenyl substituted triazine derivatives and their therapeutical applications
08/09/2012US20120202817 Compounds having 4-pyridylalkylthio group as a substituent
1 ... 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 ... 2211